



NDA 21993/S-16
NDA 20704/S-33

SUPPLEMENT APPROVAL

Bayer HealthCare LLC
Attention: Mary E. Williams
US Regulatory Affairs Allergy
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981-0915

Dear Ms. Williams:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received February 2, 2018, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Claritin (loratadine) RediTabs 12 Hour orally disintegrating tablets, 5 mg and 10 mg tablets.

These “Prior Approval” sNDAs provide for the addition of two in-pack coupons (IPCs).

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

Table 1: Final Printed Labeling

Labeling Item	Date Submitted
In-pack coupon 1 (accompanying 10-count and 30-count outer containers)	02/02/2018
In-pack coupon 2 (accompanying 10-count and 30-count “Juniors” outer containers)	02/02/2018

The FPL should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate these submissions “**Final Printed Labeling for approved NDA 21993/S-16 and Final Printed labeling for approved NDA 20704/S-33.**” Approval of these submissions by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your FPL, the content of labeling (Drug Facts) should be submitted in SPL format as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes

Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at (301) 796-9618.

Sincerely,

{See appended electronic signature page}

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:

Carton and Container Labeling
In-Pack Coupons (IPCs)

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA M MICHELE
07/23/2018